Warnex Inc.

Warnex Inc.

January 09, 2006 12:35 ET

Warnex appoints V.P. Sales and Marketing

LAVAL, QC, Jan. 9 - Warnex Inc. (TSX:WNX) announced today that
Mr. Erik Yelle has joined the Company as Vice President, Sales and Marketing
of Warnex Diagnostics Inc. to lead the Company's commercialization efforts for
the Warnex™ Rapid Pathogen Detection System.

"We believe that the Warnex Rapid Pathogen Detection System is proving
itself as a best-in-class system to monitor the safety of food products as
demanded by consumers. Our initial roster of sophisticated, industry leading
clients underpins this supposition," said Mark Busgang, President and CEO of
Warnex. "With 2006 anticipated to be a pivotal year for this system, Erik
Yelle will provide the high-caliber leadership needed to motivate our sales
force and capitalize on this growing opportunity."

Mr. Yelle has over 15 years of experience in sales development and
management obtained through his various roles within a multinational leader in
the food industry, McCain Foods. His most recent position was Vice-President,
Sales and Marketing of Wong Wing Foods Inc., a McCain Foods company, where he
was responsible for the national launch of a new line of products, the
restructuring of various departments and all aspects of the marketing

"I am familiar with the behavioral process food producers employ in
adopting new methods and believe they are increasingly receptive to innovative
pathogen detection technology. I believe this type of technology is quickly
becoming a critical factor in their continued success," said Mr. Yelle. "As
such, I am excited about expanding the Warnex System's emerging footprint."

About Warnex

Warnex (www.warnex.ca) is a publicly traded (TSX: WNX) Canadian
biotechnology company devoted to protecting public health by providing
advanced diagnostic and quality control products and services to the
pharmaceutical, agri-food, and healthcare sectors. Warnex's genomics-based
technology offers a versatile detection platform that produces accurate
results rapidly, using Real-Time PCR technology combined with unique genetic
markers and software. Applications range from pathogen detection in foods to
GMO testing. Our development pipeline includes applications in the detection
of viruses, toxins, yeasts, and fungi, as well as meat speciation and
bioterrorism. Warnex's profitable and growing analytical, bioanalytical, and
clinical service groups offer a variety of quality control services, method
development and validation, contract R&D, bioavailability and bioequivalence
studies for clinical trials, and medical laboratory testing.

Warnex is a trademark of Warnex Inc.


Certain statements contained in this news release are forward-looking
and are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to the early
commercialization of Warnex products, intellectual property and licensing,
R&D of new Warnex products, manufacturing and laboratory facilities,
suppliers, key employees, key customers, financial resources and credit risk,
government regulations, foreign currency risk and volatility of share price,
and other important factors that could cause actual results to differ
materially from those anticipated in the forward-looking statements, please
refer to the heading Risks and Uncertainties in the Management's Discussion
and Analysis for the third quarter ended on September 30, 2005, which can be
found at www.sedar.com. Consequently, actual results may differ materially
from the anticipated results expressed in these forward-looking statements.

Contact Information